Hyperinsulinemic euglycemic clamp

ApprovedSmall molecule

Hyperinsulinemic euglycemic clamp is one of 83 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

ObesityActive, not recruiting

Type 1 DiabetesActive, not recruiting

Insulin ResistancePhase 1

Active, not recruiting

ObesityApproved

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Hyperinsulinemic euglycemic clamp

TTurku University Hospital

Approved

1 2

Actemra

Roche

Preclinical

2 3

Amidate

Pfizer

Preclinical

—4

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Colcrys

Alnylam Pharmaceuticals

Cetrotide

2 9

Oxycontin

PProtega

Preclinical

1 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Type 1 Diabetes

NCT06105931

Clinical

Trials by Indication[1]

Insulin Sensitivity3 trials

Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects

Completed·—·Phase 1·NCT03234751·6 enrolled

Fatty Acid Oxidation Defects and Insulin Sensitivity

Completed·OOregon Health and Science University·N/A·NCT02517307·41 enrolled

Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity

Completed·TTurku University Hospital·N/A·NCT02933645·10 enrolled

Insulin resistance2 trials

Protection Against Insulin Resistance in Obesity

Completed·UUniversity of Michigan·N/A·NCT02717832·26 enrolled

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

Completed·VVanderbilt University·Phase 1·NCT02971202·33 enrolled

Type 1 Diabetes1 trial

Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

Recruiting·YYale University·Phase 1·NCT06105931·15 enrolled

Obesity1 trial

Total-body Glucose Utilization in Obesity

Recruiting·TTurku University Hospital·Phase 4·NCT06739473·60 enrolled

Metabolism1 trial

Assessment of Liver Glucose Metabolism in Diabetic Subjects

Completed·GGerman Diabetes Center·N/A·NCT01397279·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Hyperinsulinemic euglycemic clamp. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperinsulinemic euglycemic clamp compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperinsulinemic euglycemic clamp. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Turku University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTurku University Hospital

Hyperinsulinemic euglycemic clamp

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Insulin Sensitivity3 trials

Insulin resistance2 trials

Type 1 Diabetes1 trial

Obesity1 trial

Metabolism1 trial

References

Drug Info

Quick Facts

Related News